<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765439</url>
  </required_header>
  <id_info>
    <org_study_id>VSL#3-2013-CR</org_study_id>
    <nct_id>NCT01765439</nct_id>
  </id_info>
  <brief_title>The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iscare i.v.f., Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CD Investments srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine, whether administration of VSL#3 (Original De Simone&#xD;
      formulation) probiotic preparation can alter the bile acid metabolism in patients with&#xD;
      inflammatory bowel disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VSL#3 (Original De Simone formulation, further abbreviated as VSL#3), a potent probiotic&#xD;
      preparation, has been tested as an adjuvant therapy in inflammatory bowel diseases (IBD),&#xD;
      chronic unspecific inflammatory disorders of the gastrointestinal tract (the most frequent&#xD;
      forms of IBD are Crohn's disease (CD) and ulcerative colitis (UC)). VSL#3 has been shown to&#xD;
      improve symptoms of IBD both in animal models and in humans-the most impressive results have&#xD;
      been observed in preventing of pouchitis in UC patients. Several possible mechanisms of its&#xD;
      action have been suggested, including change in gut microbial diversity, immunomodulatory&#xD;
      function (upregulation of interleukine-10), etc., however, the list is probably far from&#xD;
      complete.&#xD;
&#xD;
      Bile acids (BA) play an important role in the gastrointestinal tract - besides facilitating&#xD;
      fat (and protein) digestion and resorption, they act as general antimicrobial agents within&#xD;
      the small intestine (maintaining the small intestine more or less microbe-free), colonic&#xD;
      microflora modifiers, intestinal innate immunity regulators, and importantly as signalling&#xD;
      molecules on the liver-intestine/intestine-liver axis. Under pathological conditions (such as&#xD;
      BA malabsorption) BA can worsen the IBD symptoms (namely diarrhoea), by irritating colonic&#xD;
      mucosa or by inducing colonic secretion of electrolytes.&#xD;
&#xD;
      The study hypothesis is that the beneficial effect of VSL#3 might be partially explained by&#xD;
      alteration of BA metabolism. There exists a complex crosstalk between gut microflora and BA:&#xD;
      BA affect microbial growth, whereas BA structure is modified by bacteria (deconjugation, 7 α&#xD;
      dehydroxylation). Several observations might support this hypothesis: VSL#3 ameliorates&#xD;
      symptoms of radiation or chemotherapy induced diarrhoea, as well as diarrhoea of critically&#xD;
      ill patients - conditions, that can be caused by BA malabsorption. Similarly, oxalate&#xD;
      absorption (closely related to BA malabsorption) has been shown to be lowered by VSL#3. The&#xD;
      main question to be addressed in the proposed study is, therefore, whether VSL#3&#xD;
      administration can somehow change metabolism of bile acids (BA).&#xD;
&#xD;
      Additionally, urinary metabolite levels are strongly influenced by differences in the&#xD;
      intestinal microbiota, since both gut bacterial metabolism, and shared metabolism by the host&#xD;
      and bacterial species ('co-metabolism'), generate specific metabolic products. Such&#xD;
      metabolites may therefore be used as markers of microbial metabolic activity, reflecting&#xD;
      systemic, functional differences. This application of urinary metabolic profiling avoids the&#xD;
      technical difficulties, and methodological differences, found in molecular studies of the&#xD;
      intestinal microbiota in IBD, which have contributed to often discrepant findings. Specific&#xD;
      urinary metabolites related to gut microbial metabolism differ between CD patients, UC&#xD;
      patients, and controls. The emerging technique of urinary NMR-based metabolic profiling with&#xD;
      multivariate analysis was able to distinguish these cohorts. This study should address the&#xD;
      question, whether VSL#3 administration changes the nuclear magnetic resonance-based urinary&#xD;
      metabolomic profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration in the rate of bile acid synthesis</measure>
    <time_frame>Baseline and 6 weeks (plus or minus 5 days)</time_frame>
    <description>Will be assessed as difference between serum levels of fibroblast growth factor 19 and C4 at baseline and 6 weeks, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the spectrum of bile acids in stools and plasma</measure>
    <time_frame>Baseline and 6 weeks (plus or minus 5 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of a metabolomic profile in urine</measure>
    <time_frame>Baseline and 6 weeks (plus or minus 5 days).</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of the disease activity</measure>
    <time_frame>Baseline and 6 weeks (plus or minus 5 days).</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>CD resected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Crohn´s disease with the history of single resection (&lt;60 cm) of distal leum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC unoperated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ulcerative colitis without history of gut resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UC IPAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects without any sign of disease of the digestive tract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3 (Original De Simone formulation)</intervention_name>
    <description>Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).</description>
    <arm_group_label>CD resected</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>UC IPAA</arm_group_label>
    <arm_group_label>UC unoperated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm CD resected&#xD;
&#xD;
          -  confirmed diagnosis of Crohn´s disease (at least 6 months)&#xD;
&#xD;
          -  history of single resection of terminal ileum (at least 6 months before inclusion)&#xD;
&#xD;
          -  maximum length of resected ileum is 60 cm&#xD;
&#xD;
          -  no signs of disease activity (clinical, endoscopical, laboratory)&#xD;
&#xD;
          -  stable medication&#xD;
&#xD;
        Arm UC unoperated&#xD;
&#xD;
          -  confirmed diagnosis of ulcerative colitis (at least 6 months)&#xD;
&#xD;
          -  no signs of disease activity (clinical, endoscopical, laboratory)&#xD;
&#xD;
          -  stable medication&#xD;
&#xD;
        Arm UC IPAA&#xD;
&#xD;
          -  confirmed diagnosis of ulcerative colitis (at least 6 months)&#xD;
&#xD;
          -  proctocolectomy and IPAA (at least 3 months before inclusion)&#xD;
&#xD;
          -  no signs of disease activity (clinical, endoscopical, laboratory)&#xD;
&#xD;
          -  stable medication&#xD;
&#xD;
        Arm Healthy volunteers&#xD;
&#xD;
          -  no signs of gastrointestinal disorder&#xD;
&#xD;
          -  initial laboratory examination within normal range (blood count, liver function tests,&#xD;
             C-reactive protein, Fe, ferritin, fecal calprotectin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of bile acids&#xD;
&#xD;
          -  use of bile acids sequestrants&#xD;
&#xD;
          -  use of farnesoid X receptor agonists/antagonists&#xD;
&#xD;
          -  recent colonoscopy(less than 1 month before inclusion)&#xD;
&#xD;
          -  diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lenicek, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iscare I.V.F.</name>
      <address>
        <city>Prague</city>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Martin Lenicek</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>bile acids</keyword>
  <keyword>metabolism</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

